First Albany Keeps Buy on OSI Pharmaceuticals

The drugmaker says a Phase III study of cancer drug Tarceva met its target

First Albany keeps the buy rating on OSI Pharmaceuticals (OSIP ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.